pembrolizumab + plinabulin + etoposide + platinum

This is a combination therapy being investigated for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). The regimen combines pembrolizumab (a PD-1 inhibitor), plinabulin (a dendritic cell maturation agent), and standard chemotherapy with etoposide plus platinum (either carboplatin or cisplatin). The combination aims to address the rapid progression observed in ES-SCLC patients by potentially enhancing immune response and increasing treatment durability. Plinabulin's unique dendritic cell maturation mechanism may serve as a bridge between tumor neo-antigen generation from chemotherapy and T-cell action enabled by PD-1 antibodies, potentially enabling more durable responses and improved progression-free survival.